Wedbush Equities Analysts Lower Earnings Estimates for HOWL

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) – Investment analysts at Wedbush decreased their FY2025 earnings estimates for Werewolf Therapeutics in a research note issued to investors on Wednesday, March 12th. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of ($1.84) for the year, down from their prior estimate of ($0.97). Wedbush has a “Outperform” rating and a $8.00 price target on the stock. The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.56) per share. Wedbush also issued estimates for Werewolf Therapeutics’ FY2026 earnings at ($1.13) EPS, FY2027 earnings at ($1.57) EPS, FY2028 earnings at ($1.63) EPS and FY2029 earnings at ($0.63) EPS.

Other equities analysts have also issued research reports about the stock. JMP Securities decreased their price objective on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a research note on Tuesday, January 14th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a research note on Wednesday, March 12th.

Werewolf Therapeutics Trading Down 2.5 %

Shares of NASDAQ:HOWL opened at $1.17 on Monday. The stock has a market capitalization of $52.45 million, a price-to-earnings ratio of -0.76 and a beta of 0.37. Werewolf Therapeutics has a 1-year low of $1.03 and a 1-year high of $6.89. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. The company has a 50 day moving average price of $1.34 and a 200 day moving average price of $1.79.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Tuesday, March 11th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%.

Hedge Funds Weigh In On Werewolf Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in Werewolf Therapeutics by 6.3% in the 3rd quarter. Geode Capital Management LLC now owns 685,989 shares of the company’s stock worth $1,454,000 after buying an additional 40,692 shares in the last quarter. Barclays PLC lifted its position in Werewolf Therapeutics by 130.1% in the 3rd quarter. Barclays PLC now owns 54,810 shares of the company’s stock worth $116,000 after buying an additional 30,990 shares in the last quarter. State Street Corp lifted its position in Werewolf Therapeutics by 12.4% in the 3rd quarter. State Street Corp now owns 476,439 shares of the company’s stock worth $1,010,000 after buying an additional 52,528 shares in the last quarter. Walleye Capital LLC lifted its position in Werewolf Therapeutics by 10.7% in the 3rd quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock worth $231,000 after buying an additional 10,528 shares in the last quarter. Finally, Levin Capital Strategies L.P. purchased a new stake in Werewolf Therapeutics in the 4th quarter worth approximately $74,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.